Inovio Pharmaceuticals Inc (NASDAQ:INO) CEO Jong Joseph Kim sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $3.31, for a total transaction of $331,000.00. Following the transaction, the chief executive officer now owns 2,411,055 shares of the company’s stock, valued at approximately $7,980,592.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Jong Joseph Kim also recently made the following trade(s):
- On Thursday, May 16th, Jong Joseph Kim sold 136,768 shares of Inovio Pharmaceuticals stock. The stock was sold at an average price of $3.50, for a total transaction of $478,688.00.
NASDAQ:INO traded down $0.01 during trading hours on Friday, hitting $3.24. 21,818 shares of the company were exchanged, compared to its average volume of 1,184,935. The company has a market cap of $318.61 million, a PE ratio of -3.09 and a beta of 1.70. Inovio Pharmaceuticals Inc has a 52-week low of $3.02 and a 52-week high of $6.30. The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 1.02.
Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.01). The company had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $4.44 million. Inovio Pharmaceuticals had a negative return on equity of 97.95% and a negative net margin of 295.24%. As a group, analysts expect that Inovio Pharmaceuticals Inc will post -1.01 EPS for the current fiscal year.
INO has been the subject of several recent analyst reports. HC Wainwright initiated coverage on shares of Inovio Pharmaceuticals in a research note on Thursday, May 16th. They set a “buy” rating and a $13.00 price objective for the company. BidaskClub lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 7th. Maxim Group reissued a “buy” rating and set a $8.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, April 3rd. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Thursday, February 7th. Finally, Cantor Fitzgerald began coverage on shares of Inovio Pharmaceuticals in a research report on Monday, March 25th. They set an “overweight” rating and a $3.62 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Inovio Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $7.57.
Large investors have recently added to or reduced their stakes in the business. Quantamental Technologies LLC purchased a new stake in Inovio Pharmaceuticals during the 4th quarter worth approximately $43,000. Defender Capital LLC. purchased a new stake in shares of Inovio Pharmaceuticals in the 4th quarter valued at $2,324,000. Dimensional Fund Advisors LP boosted its holdings in shares of Inovio Pharmaceuticals by 41.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 737,962 shares of the biopharmaceutical company’s stock valued at $2,952,000 after acquiring an additional 217,536 shares during the last quarter. Pembroke Management LTD purchased a new stake in shares of Inovio Pharmaceuticals in the 4th quarter valued at $52,000. Finally, Paloma Partners Management Co boosted its holdings in shares of Inovio Pharmaceuticals by 38.7% in the 4th quarter. Paloma Partners Management Co now owns 16,201 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 4,522 shares during the last quarter. 46.01% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thestockobserver.com/2019/05/24/jong-joseph-kim-sells-100000-shares-of-inovio-pharmaceuticals-inc-ino-stock.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Article: Different Types of Derivatives
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.